Understanding the Role of Coagulation and Inflammation in Chronic Liver Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the roles of coagulation, inflammation, and vascular changes in the onset and progression of chronic liver diseases. By analyzing patients with chronic liver disease and comparing them to healthy controls, the study seeks to identify key biomarkers and mechanisms that contribute to these conditions. The findings could enhance patient management and inform healthcare strategies for chronic liver diseases, which significantly impact quality of life and economic resources. The study will utilize biomarker assays to gather relevant data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients with chronic liver disease:

Patients over 18 years of age Patients affiliated with a social security plan or entitled to receive benefits Patients with chronic liver disease or cirrhosis whose diagnosis is based on one or more of the following

* Liver biopsy showing chronic liver disease or cirrhosis
* Liver elastography by Fibroscan® assessing the elasticity of the liver at more than 10 kpa
* Combination of clinical, biological and imaging criteria characteristic of chronic liver disease (signs of portal hypertension, liver failure and liver dysmorphia in a patient with at least one risk factor for chronic liver disease)

Controls without liver disease Patients 18 years of age with no known liver disease Patients who have had blood drawn in the hospital prior to surgery (pre-operative work-up as part of the care process).

Exclusion Criteria:

Common non-inclusion criteria for patients with chronic liver disease and controls without liver disease will be as follows:

* Pregnant or lactating women
* Protected populations: persons under guardianship, under curatorship or safeguard of justice
* Patient under AME
* Patient who has not signed a consent form
* Recent surgery before the blood test (\< 2 weeks)
* Transfusion of blood products (packed red blood cells, platelet concentrates, fresh frozen plasma, etc.) recently (\< 2 weeks)
* Use of medication that interferes with hemostasis
* Active extra-hepatic cancer or cancer less than 5 years old
* Organ transplantation (liver, kidney, lung, heart)

Where it's running

• Beaujon Hospital
  Clichy, France Recruiting

Study contacts

• Principal investigator: Pierre Emmanuel Rautou — Aphp
• Study coordinator: Pierre Emmanuel Rautou
• Email: pierre-emmanuel.rautou@aphp.fr
• Phone: 140875283

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Perosphere ClotChek whole-blood clotting test for people on rivaroxaban or apixaban

  This project will see if the Perosphere ClotChek device can accurately measure whole blood clotting time in adults taking the blood thinners rivaroxaban or apixaban.

  Recruiting at 4 sites Perosphere Technologies Inc. · Danbury, Connecticut and 3 other locations · NCT07012291

• Observational study on young adults with ischemic stroke

  This study looks at young adults aged 18-50 who have had a stroke to see what causes it and how to better treat and prevent strokes in this age group.

  Recruiting Radboud University Medical Center · Nijmegen, Gelderland and 5 other locations · NCT05853796

• Analyzing blood clotting in hospitalized COVID-19 patients with severe pneumonia

  This study looks at how COVID-19 affects blood clotting in hospitalized patients with severe pneumonia to see if it can help improve their treatment.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT04377490

• Evaluating immune cell activity in patients undergoing heart surgery

  This study is trying to see how immune cell activity during heart surgery affects the risk of blood clots in patients.

  Recruiting Boston Children's Hospital · Boston, Massachusetts · NCT04299828

• Reltodecacog alfa plus usual care in adults needing urgent surgery while on a FXa DOAC

  Aims to see if reltodecacog alfa can help blood clot faster during urgent surgery in adults taking FXa DOACs, compared with the usual care.

  Recruiting at 65 sites Phase 3 VarmX B.V. · Chandler, Arizona and 76 other locations · NCT07288489

• Reducing postpartum blood loss with coagulation factor XIII

  This study is testing if giving a treatment called coagulation factor XIII can help reduce heavy bleeding after childbirth in women who have had a vaginal delivery.

  Recruiting at 8 sites Phase 4 University of Zurich · Geneva, Canton of Geneva and 8 other locations · NCT06481995

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.